NCT03506373View on ClinicalTrials.gov

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

February 6, 2023

Study Completion Date

June 23, 2025

Conditions
Recurrent Waldenstrom MacroglobulinemiaRefractory Waldenstrom MacroglobulinemiaWaldenstrom Macroglobulinemia
Interventions
DRUG

Ibrutinib

Given PO

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacodynamic Study

Correlative studies

OTHER

Pharmacokinetic Study

Correlative studies

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03506373 - Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | Biotech Hunter | Biotech Hunter